Pharma Newsletter – September 4 to September 8, 2017

India Infoline News Service | Mumbai | September 09, 2017 09:47 IST

This week, “The share of Cadila Healthcare surged by over 3% intraday during Thursday’s trading session after hat the company informed that USFDA has completed the inspection of its Moraiya facility.”

Top news:
 
USFDA completes inspection of Cadila Healthcare’s Moraiya unit

The share of Cadila Healthcare surged by over 3% intraday during Thursday’s trading session after hat the company informed that USFDA has completed the inspection of its Moraiya facility. Read more
 
Dr. Reddy Lab launches Metaxalone tablets in US
 
Pharma major, Dr. Reddy Laboratories announced that it has received the US Food and Drug Administration (USFDA) approval to market Metaxalone tablets, USP 800 mg, the company informed in the filing to the bourses on Wednesday. Read more
 
JDRF supports Biocon study of type 1 diabetes treatment
 
Asia’s premier biopharmaceuticals company, and JDRF, the leading global organization funding type 1 diabetes (T1D) research and advocacy worldwide, jointly announced a JDRF partnership to support a global multiple ascending dose study with a novel oral insulin drug candidate, Insulin Tregopil, in people with T1D.Read more

Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.